Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates.

Milani M, Annoni A, Moalli F, Liu T, Cesana D, Calabria A, Bartolaccini S, Biffi M, Russo F, Visigalli I, Raimondi A, Patarroyo-White S, Drager D, Cristofori P, Ayuso E, Montini E, Peters R, Iannacone M, Cantore A, Naldini L.

Sci Transl Med. 2019 May 22;11(493). pii: eaav7325. doi: 10.1126/scitranslmed.aav7325.

PMID:
31118293
2.

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.

Krishnamoorthy S, Liu T, Drager D, Patarroyo-White S, Chhabra ES, Peters R, Josephson N, Lillicrap D, Blumberg RS, Pierce GF, Jiang H.

Cell Immunol. 2016 Mar;301:30-9. doi: 10.1016/j.cellimm.2015.12.008. Epub 2015 Dec 29.

3.

FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.

van der Flier A, Liu Z, Tan S, Chen K, Drager D, Liu T, Patarroyo-White S, Jiang H, Light DR.

PLoS One. 2015 Apr 23;10(4):e0124930. doi: 10.1371/journal.pone.0124930. eCollection 2015.

4.

A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.

Buyue Y, Liu T, Kulman JD, Toby GG, Kamphaus GD, Patarroyo-White S, Lu Q, Reidy TJ, Mei B, Jiang H, Pierce GF, Sommer JM, Peters RT.

PLoS One. 2014 Nov 21;9(11):e113600. doi: 10.1371/journal.pone.0113600. eCollection 2014.

5.

Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy.

Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA, Zhou S, Scallan CD, Sommer J, Vijay S, Mingozzi F, High KA, Pierce GF.

Blood. 2006 Nov 15;108(10):3321-8. Epub 2006 Jul 25.

6.

Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).

Liu T, Scallan CD, Broze GJ Jr, Patarroyo-White S, Pierce GF, Johnson KW.

Thromb Haemost. 2006 Jan;95(1):68-76.

PMID:
16543964
7.

Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.

Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, Scallan CD, Powell S, Keller T, McMurray M, Labelle A, Nagy D, Vargas JA, Zhou S, Couto LB, Pierce GF.

Blood. 2006 Jul 1;108(1):107-15. Epub 2006 Mar 7.

PMID:
16522813
8.

Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties.

Arbetman AE, Lochrie M, Zhou S, Wellman J, Scallan C, Doroudchi MM, Randlev B, Patarroyo-White S, Liu T, Smith P, Lehmkuhl H, Hobbs LA, Pierce GF, Colosi P.

J Virol. 2005 Dec;79(24):15238-45.

9.

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, Couto LB, Pierce GF.

Blood. 2006 Mar 1;107(5):1810-7. Epub 2005 Oct 25.

PMID:
16249376
10.

Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.

Scallan CD, Liu T, Parker AE, Patarroyo-White SL, Chen H, Jiang H, Vargas J, Nagy D, Powell SK, Wright JF, Sarkar R, Kazazian HH, McClelland A, Couto LB.

Blood. 2003 Dec 1;102(12):3919-26. Epub 2003 Jul 31.

PMID:
12893764
11.

Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.

Scallan CD, Lillicrap D, Jiang H, Qian X, Patarroyo-White SL, Parker AE, Liu T, Vargas J, Nagy D, Powell SK, Wright JF, Turner PV, Tinlin SJ, Webster SE, McClelland A, Couto LB.

Blood. 2003 Sep 15;102(6):2031-7. Epub 2003 May 8.

PMID:
12738670
12.

Regulatable liver expression of the rabbit apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) in mice lacking endogenous APOBEC-1 leads to aberrant hyperediting.

Hersberger M, Patarroyo-White S, Qian X, Arnold KS, Rohrer L, Balestra ME, Innerarity TL.

Biochem J. 2003 Jan 15;369(Pt 2):255-62.

14.

Supplemental Content

Loading ...
Support Center